Abstract
Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Keywords: Mesenchymal stem/stromal cells, cell therapy, graft versus host disease, immunomodulatory properties, regenerative medicine, advanced therapy medicinal product, transplantation, MSCs sources, clinical trials, clinical applications
Current Pharmaceutical Design
Title:Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Volume: 19 Issue: 13
Author(s): Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D’Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina and Maria Luisa Torre ; Italian Mesenchymal Stem Cell Group (GISM)
Affiliation:
Keywords: Mesenchymal stem/stromal cells, cell therapy, graft versus host disease, immunomodulatory properties, regenerative medicine, advanced therapy medicinal product, transplantation, MSCs sources, clinical trials, clinical applications
Abstract: Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Export Options
About this article
Cite this article as:
de Girolamo Laura, Lucarelli Enrico, Alessandri Giulio, Antonietta Avanzini Maria, Ester Bernardo Maria, Biagi Ettore, Teresa Brini Anna, D’Amico Giovanna, Fagioli Franca, Ferrero Ivana, Locatelli Franco, Maccario Rita, Marazzi Mario, Parolini Ornella, Pessina Augusto and ; Italian Mesenchymal Stem Cell Group (GISM) Luisa Torre Maria, Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130015
DOI https://dx.doi.org/10.2174/1381612811319130015 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet the Editorial Board Member
Current Drug Targets Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Preface
Recent Patents on Medical Imaging Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Antithrombotic Treatment Management in Patients with Intracerebral Hemorrhage: Reversal and Restart
Current Pharmaceutical Design Statins in Aortic Disease
Current Pharmaceutical Design Chagas Heart Disease Pathogenesis: One Mechanism or Many?
Current Molecular Medicine Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update
Current Vascular Pharmacology Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design